低剂量米力农治疗≥80岁慢性心力衰竭患者的效果

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF (0 KB) HTML (34 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察低剂量米力农治疗≥80 岁慢性心力衰竭（CHF）患者的效果。方法选取2018年10月～2019年10月我院收治的60 例≥80 岁CHF 患者，依据随机数字表法分为治疗组和对照组，各30 例。治疗组采用标准治疗+低剂量米力农，对照组采用标准治疗。比较两组的治疗总有效率、血压、心率、左室射血分数（LVEF）值、左室舒张末期内径（LVEDD）、左室收缩末期内径（LVESD）、左室收缩末期容积（LVESV）、左室舒张末期容积（LVEDV）和6 min步行试验距离。结果治疗组的总有效率为86.7%，显著高于对照组的53.3%，差异有统计学意义（P＜0.01）。治疗组的LVEF[（57.2±9.3）%]、6 min 步行试验距离[（499.5±50.2）m]明显高于对照组[（45.7±8.8）%、（392.5±90.8）m]，差异有统计学意义（P＜0.01）。治疗组的LVESV[（116.3±52.7）ml]、LVEDV[（192.6±45.4）ml]、LVESD[（47.4±6.3）mm]低于对照组[（126.2±41.5）ml、（201.9±50.2）ml、（50.2±8.6）mm]，差异有统计学意义（P＜0.05）。治疗组的LVEDD 为（60.6±10.1）mm，与对照组的（61.2±10.8）mm 比较，差异无统计学意义（P＞0.05）。治疗组治疗后的LVEF[（57.2±9.3）%]、6 min 步行试验距离[（499.5±50.2）m]显著高于治疗前[（37.3±11.4）%、（246.6±72.2）m]，差异有统计学意义（P＜0.01）。治疗组治疗后的LVESV、LVEDV、LVEDD、LVESD 低于治疗前，差异有统计学意义（P＜0.05）；对照组治疗后的LVEF、6 min 步行试验距离高于治疗前，差异有统计学意义（P＜0.05）。对照组治疗前后的LVESV、LVEDV、LVESD、LVEDD 比较，差异均无统计学意义（P＞0.05）。两组患者治疗前后的血压、心率比较，差异无统计学意义（P＞0.05）。结论低剂量米力农能明显改善≥80 岁CHF 患者的心功能及运动耐量。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	唐爱
	杨贵志

关键词 ：慢性心力衰竭, 米力农, 高龄, 6 min 步行试验, 超声检查, 临床疗效

Abstract：Objective To observe the effect of low-dose Milrinone in the treatment of chronic heart failure (CHF) patients over 80 years old.Methods A total of 60 patients over 80 years old with CHF were selected and divided into the treatment group and the control group by random number table method, 30 cases in each group.The treatment group was treated with standard treatment combined with low-dose Milrinone, and the control group was treated with standard treatment.The total effective rate, blood pressure, heart rate, left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), left ventricular end systolic volume(LVESV), left ventricular end diastolic volume (LVEDV) and 6-minute walking test distance were compared between the two groups.Results The total effective rate was 86.7% in the treatment group, which was significantly higher than that in the control group (53.3%), the difference was statistically significant (P＜0.01).The LVEF ([57.2±9.3]%) and 6-minute walking test distance [(499.5±50.2) m] in the treatment group were higher than those in the control group([45.7±8.8]% and [392.5±90.8] m), the differences were statistically significant (P＜0.01).The LVESV ([116.3±52.7]ml),LVEDV ([192.6±45.4] ml) and LVESD ([47.4±6.3] mm) in the treatment group were lower than those in the control group ([126.2±41.5] ml, [201.9±50.2] ml and [50.2±8.6] mm), with statistical significances (P＜0.05).The LVEDD in the treatment group was (60.6±10.1) mm, which in the control group was (61.2±10.8) mm, with no statistical significance(P＞0.05).The LVEF ([57.2±9.3]%), 6-minute walking test distance ([499.5±50.2] m) in the treatment group after treatment were higher than those before treatment ([37.3±11.4]%, [246.6±72.2] m), the differences were statistically significant (P＜0.01).The LVESD, LVEDD, LVEDV and LVESV in the treatment group after treatment were lower than those before treatment, the differences were statistically significant (P＜0.05).The LVEF and 6-minute walking test distance of the control group after treatment were higher than those before treatment, the differences were statistically significant(P＜0.05).There were no significant differences in LVESV, LVEDV, LVESD and LVEDD between the control group before and after treatment (P＞0.05).There were no significant differences in blood pressure and heart rate between the two groups before and after treatment (P＞0.05).Conclusion The low-dose Milrinone can significantly improve heart function and exercise tolerance in elderly patients over 80 years old.

Key words： Chronic heart failure Milrinone Elderly 6-minute walking test Ultrasound Clinical efficacy

引用本文:

唐爱；杨贵志. 低剂量米力农治疗≥80岁慢性心力衰竭患者的效果[J]. 中国当代医药, 2020, 27(22): 69-72.
TANG Ai；YANG Gui-zhi. Effect of low-dose Milrinone in the treatment of chronic heart failure patients over 80 years old. 中国当代医药, 2020, 27(22): 69-72.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I22/69

[1]	Vecchis R，Cesaro A，Ariano C.Therapeutic benefits of phosphodi-esterase-5 inhibition in chronic heart failure：a meta-analysis[J].Interv Med Appl Sci，2017，9（3）：123-135.
[2]	Zhang Y，Zhang J，Butler J，et al.Contemporary epidemiology，management，and outcomes of patients hospitalized for heart failure in China：results from the China Heart Failure（China-HF）Registry[J].J Card Fail，2017，23（12）：868-875.
[3]	Petrov VN，Agaeva EV，Popovkina OE，et al.Modifying ef fect of autotransfusion of mesenchymal stromal cells on the production of reactive oxygen species and cytokines by mononuclear cells in patients with chronic heart failure[J].Bull Exp Biol Med，2017，164（2）：233-240.
[4]	顾东风，黄广勇，何江，等.中国心力衰竭流行病学调查及其患病率[J].中华心血管病杂志，2003，31（1）：3-6.
[5]	Zile MR，Brutsaert DL.New concepts in diastolic dysfunction and diastolic heart failure：part Ⅰ：diagnosis，prognosis，measurement of diastolic function[J].Circulation，2002，105（10）：1387-1393.
[6]	Cody RJ，Haas GJ，Binkley PF，et al.Plasma endothelin correlate with the extent of pulmonary hypertension in patients with chronic congestive heart failure[J].Circulation，1992，85（2）：504-509.
[7]	杨杰孚，王华，柴坷.2018 中国心力衰竭诊断和治疗指南亮点[J].中国心血管病研究，2018，16（12）：1057-1060.
[8]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[9]	杨杰孚，李莹莹.从《中国心力衰竭诊断和治疗指南2018》看容量管理[J].临床药物治疗杂志，2019，17（10）：10-14.
[10]	阎祷.米力农治疗慢性肺心病合并心力衰竭急性加重期的临床疗效观察[J].中国医刊，2012，47（4）：57-58.
[11]	魏安华，李娟.《中国心力衰竭诊断和治疗指南2018》药物更新透视[J].医药导报，2019，38（5）：539-543.
[12]	张建军.接轨国际指南、彰显中国特色《中国心力衰竭诊断和治疗指南2018》解读[J].中国临床医生杂志，2019，47（4）：398-402.
[13]	胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要[J].中国循环杂志，2019，34（3）：209-220.
[14]	葛俊波，徐永健，王辰.内科学[M].9 版.北京：人民卫生出版社，2018：173-176.
[15]	王绥标，康福新，陈梁，等.米力农对老年慢性心力衰竭急性加重期的疗效及对心功能的影响[J].中国药业，2018，27（6）：27-29.
[16]	Birger A，Mikael A，Anders M，et al.Milrinone improves diastolic function in coronary artery bypass surgery as assessed by acoustic quantification and peak filling rate：a prospective randomized study[J].J Cardiothorac Vasc Anesth，2010，24（2）：244-249.
[17]	Watanabe H，Kajimoto K，Kawana M.Combination therapy with PDE Ⅲinhibitor for heart failure[J].Nippon Rinsho，2007，65（Suppl 5）：134-139.